1. Medtech Insight
  2. >>Device Area
  3. >>Combination Products

Angiotech's New Partnering Model for the Convergence Era

Angiotech Pharmaceuticals, a company that has grabbed the new paradigm of convergence by both horns, has amassed intellectual property on drugs and acquired a broad array of biomaterials. Now, to access innovative medical devices, it has embarked upon a new partnering model, and the agreement that it just signed with CABG Medical is only the first example of its new style of dealmaking.

While the major pharmaceutical and medical device companies, apart from their drug-eluting stent projects, continue to sit somewhat on the sidelines of the convergence melee, mid-sized Angiotech Pharmaceuticals Inc. (with 2004 sales of $130 million from its shares of royalties on the Boston Scientific Corp. Taxus drug-eluting stent [See Deal]) has jumped in with both hands and feet. Speaking in mid-March at "Convergence: The Drug/Device Summit," a conference organized by Bio, AdvaMed, the Pittsburgh Life Sciences Greenhouse and MedTech Insight, Windhover Information Inc., Angiotech's chief business officer Jeanne Bertonis articulated the company's strategy to bring biological solutions to bear on the shortcomings of device interventions.

That mandate sounds like it encompasses an overwhelming breadth of applications for a company that's not large, but Bertonis explains...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Combination Products

Novel Pathway For Combined Drug/IVD Trials Wins Backing Of EU Nations

 
• By Vibha Sharma

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.

New Draft Guidance Clarifies FDA’s UDI Rules For Combination Products

 
• By Elizabeth Orr

The FDA has released draft guidance clarifying UDI rules for drug- and device-led combination products. The document specifies labeling requirements and makes recommendations to reduce confusion between UDIs and NDCs. Comments are being accepted until Sept. 24.

European Commission Asks For ‘Open Minds’ On Unified Drug/Device Research Pathway

 
• By Vibha Sharma

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

Serious Injuries Tied To Medtronic Bravo GERD Diagnosing System

 
• By Brian Bossetta

The US FDA has issued an early alert to notify consumers about serious risks associated with a recall from Medtronic and its subsidiary Given Imaging. The alert concerns delivery capsules for diagnosing GERD.

More from Device Area

‘Be Quick, But Don’t Hurry’: Dexcom CEO Talks CGM Market Success

 
• By Marion Webb

Dexcom’s CEO Kevin Sayer discusses this fall’s planned launch of the 15-day G7 CGM, downplays Abbott’s dual-sensor while focusing on development of multi-analyte G8, making OTC Stelo app more “consumerish” for Europeans, and more.

New Draft Guidance Clarifies FDA’s UDI Rules For Combination Products

 
• By Elizabeth Orr

The FDA has released draft guidance clarifying UDI rules for drug- and device-led combination products. The document specifies labeling requirements and makes recommendations to reduce confusion between UDIs and NDCs. Comments are being accepted until Sept. 24.

Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring

 
• By Natasha Barrow

“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.